HPLC and Densitometric TLC Methods for Simultaneous Determination of Pazufloxacin with Some Co-Administered Drugs in Human Plasma
- *Corresponding Author:
- Nehad A Abdallah
Experiments and Advanced Pharmaceutical Research Unit (EAPRU)
Faculty of Pharmacy, Ain Shams University, Egypt
Tel: 020 01146447587, 020 01001353678
E-mail: [email protected]
Received date: December 14, 2012; Accepted date: December 26, 2012; Published date: December 30, 2012
Citation: Abdallah NA, Ayad MF, El-Kosasy AM (2012) HPLC and Densitometric TLC Methods for Simultaneous Determination of Pazufloxacin with Some Coadministered Drugs in Human Plasma. J Chromat Separation Techniq 3:161 doi:10.4172/2157-7064.1000161
Copyright: © 2012 Abdallah NA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Two chromatographic methods have been developed for determination of pazufloxacin in human plasma with two co-administered drugs, cefoperazone and sulbactam sodium. First method depends on reverse phase high performance liquid chromatography. The plasma sample was extracted using mixture of ethyl acetate and 15% perchloric acid. The method was linear over the concentration range 0.5 to 20 μg/ml, 1 to 30 μg/ml and 1 to 25 μg/ ml of pazufloxacin mesylate, cefoperazone and sulbactam sodium, respectively. The mobile phase used consist of methanol, 0.01 M sodium acetate buffer (pH adjusted to 3 using trifluoroacetic acid) in a ratio 20:80 and 0.5% TEA and flow rate 1 ml/min in isocratic mode and UV-detection at wavelength 240 nm. Second method depends on densitometric thin layer chromatography. The method was linear over concentration range 1 to 20 μg/ml, 6 to 24 μg/ml and 4 to 20 μg/ml of pazufloxacin mesylate, cefoperazone and sulbactam sodium, respectively. The mobile phase used consists of chloroform, methanol and ammonia in the ratio of (11:6:2, v/v/v). Densitometric analysis was carried out at wavelength 240 nm. The stability of pazufloxacin mesylate and the coadministered drugs in plasma was confirmed during three freeze–thaw cycles (−20°C).